Jumpinjack, >> Probably a RS and/or dilution on the horizon <<
Yes, agreed.
Btw, concerning the enrollment in the Dronabinol Phase 2, in the Q+A at the end of yesterday's Roth presentation, Dr. Manuso said that toward the end of 2015 the trial had enrolled very close to 100 patients. So that would leave only approx 20 more to go as of late Dec, so enrollment should be close to complete. Dr. Manuso said that because the trial is being run via the NIH funding, RespireRx management doesn't have as much direct knowledge about the trial as they would have if the company was running the trial.
The timeline given at the Roth presentation was for the Dronabinol trial results in Q3-16, though at another point in the presentation he also said 'toward the end of the year', so I'm figuring it'll be sometime in the 2nd half of 2016.
Concerning the company's timeline for the CX-1739 Respiratory Depression trial, they have it starting Q1-16 and completing Q2-16, which sounds on the optimistic side to me. I remember how long the previous CX-717 RD trial took, so I'm figuring the completion date will slip some. Dr. Manuso said the trial is relatively inexpensive, and will be starting very soon, but since it doses for 4 weeks, I'm figuring on seeing results in Q3, not Q2.
But what the heck, what's a few months. The odds of success in this RD trial should be very good since it's basically a repeat of the previously successful CX-717 RD trial. The Pre-Botz Complex of the brain that controls breathing is jam packed with AMPA receptors, and Ampakines have strong activity in upregulating respiratory drive, without affecting the analgesic efficacy of the opioid, as was demonstrated in the previous CX-717 RD trial.
Should be an interesting year :o)
